#AGL

Angle PLC, the platform based diagnostic company focused on providing a cutting edge innovative approach in the fight against cancer

With a total addressable future market in the region of $51bn to $100bn per year in the US alone

#AGL

Angle's Parasortix system is poised for substantial growth and an acute market penetration over the following years

How is Angle's Parasortix system actively looking to penetrate the market?
-Diagnosing Patients
-Optimising Treatment
-Frequent treatment analysis/evaluation

#AGL

With a further scope to
-Monitor for relapse/Remission
-Population Screening

So how is this different to the current standard of diagnosis?
Current Diagnoses is by tissue biopsy, this involves a surgical procedure to take physical tissue from the patient

Angle's...

#AGL

Angle's Parasortix system enables this process via a simple, quick+easy blood sample (Liquid Biopsy)

Although they are not yet looking to make this a replacement for initial tissue biopsy, this method has numerous benefits for deployment as it is highly repeatable

#AGL

The system captures Circulating Tumour Cancers (Metastasis) from the blood sample which can then be analysed in many ways

Here is a video for a more detailed overview

#AGL

I will now explain in further detail why I believe this company is highly likely to transform into a multi billion dollar company

#AGL

Firstly focusing on their first route to market...

Metastasis Breast Cancer

A recently reviewed US Market of $2.4bn per year

Angle has been in consistent dialogue with FDA ahead of their upcoming submission for 'FDA Clearance' this month + appear to be very excited

#AGL

From their recent RNS' it is clear to say Angle have found a niche diagnostic tool that can be used to frequently and easily monitor the patient’s cancer.
By using this biological cancer cell extraction method compared to scans, this will allow...

#AGL
... the oncologists to understand the certain receptors and characteristics of each individual cancer, and how it changes and develops leading to an optimised treatment protocol and a higher intensity of supervision to quickly identify the best treatment for the cancer

#AGL

As seen in the early FDA preliminary meeting RNS
Angle are excited by the response generated by the FDA who, IMO, also believe Angles Parasortix System will play a key role in the optimisation of cancer treatment + supervision that should ultimately save patients’ lives

#AGL

Angle Parasortix System is deemed as a cheap diagnostic tool in the realms of medical bills

However, latest figures show the system and accessories sell at extremely high margins as seen below, highlighting a very successful business model once cleared for mass sales

#AGL

In the US alone 150,000 patients are living with metastasis breast cancer and under my assumptions for reoccurring revenue from the US ALONE
-20 blood tests per patient needed per year
-30 to 100% of patients= 900k to 3m Cassettes
-@ £73 profit

Annual Profit= £65m to £219m

#AGL

Using the above assumptions with a modest P/E of 10 the metastasis breast cancer industry ALONE is worth

MCap- £650m to £2.19bn

#AGL

Angle is submitting their application for FDA clearance for use in Metastasis Breast Cancer this month

With review expected to take around 6 months

Angle may well be exploiting this niche market within H1 2021

#AGL

So now let me dig a little deeper into the growing body of evidence, as researchers such as Cancer UK + other global experts are currently conducting at their own cost which will support the expansion of this cutting edge technology into other metastasis cancers